Pediatr. praxi. 2017;18(3):150-154 | DOI: 10.36290/ped.2017.027

Invasive meningococcal disease

MUDr. Jan Pavelka, MUDr. Lukáš Homola, Ph.D.
Klinika dětských infekčních nemocí, FN Brno
Lékařská fakulta Masarykovy univerzity, Brno

Due to frequent fulminant course of invasive meningococcal disease, it is essential to diagnose urgently, based on a history andclinical examination, and to initiate rational treatment within 30 minutes according to valid recommendations by parenteral 3rdgeneration cephalosporin and volumetric shock resuscitation. Vaccination is the only significant preventive measure. Post-exposureprophylaxis of risky contacts consists of penicillin administration for 7 days. Meningococcus presence in the nasopharynx iswidespread and key aspect of immunization. „Treatment“ of carriers is not indicated.

Keywords: Neisseria meningitidis, meningococcus, invasive, sepsis, shock, pathogenesis, pathogenity, colonization, carriage,
prevention, prohylaxis, first contact, treatment

Published: August 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavelka J, Homola L. Invasive meningococcal disease. Pediatr. praxi. 2017;18(3):150-154. doi: 10.36290/ped.2017.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Křížová P, Musílek M, Vacková Z, et al. Invazivní meningokokové onemocnění v České republice v roce 2016. Zprávy centra epidemiologie a mikrobiologie. SZÚ, Praha. 2017; 26(2): 60-66.
    2. Harrison O, Claus H, Jiang Y, et al. Description and Nomenclature of Neisseria meningitidis Capsule Locus. Emerg Infect Dis. 2013; 19(4): 566-573. Go to original source...
    3. Caugant D. Genetics and evolution of Neisseria meningitidis: Importance for the epidemiology of meningococcal disease. Infection, Genetics and Evolution. 2008; 8(5): 558-565. Go to original source... Go to PubMed...
    4. Yazdankhah S, Caugant D. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol. 2004; 53(Pt 9): 821-832. Go to original source...
    5. Maiden M, Bygraves J, Feil E, et al. Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA. 1998; 95: 3140-3145. Go to original source...
    6. Deuren M, Brandtzaeg P, Meer J. Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management. Clin Microbiol Rev. 2000; 13(1): 144-166. Go to original source... Go to PubMed...
    7. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systemic review and meta-analysis. Lancet Infect Dis. 2010; 10: 853-861. Go to original source... Go to PubMed...
    8. Apicella M. Neisseria meningitidis. In: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 7th ed. Philadelphia: Churchill Livingstone Elsevier; 2010: 2737-2752. Go to original source...
    9. Reller B, MacGregor R, Beaty H. Bactericidal Antibody after Colonization with Neisseria meningitidis. J Infect Dis. 1973; 127(1): 56-62. Go to original source...
    10. Guzzetta G, Manfredi P, Gasparini R, et al. On the relationship between meningococcal transmission dynamics and disease: remarks on humoral immunity. Vaccine. 2009; 27: 3429-3434. Go to original source... Go to PubMed...
    11. Goldschneider I, Gotschlich E, Artenstein M. Human immunity to the menigococcus. I. The Role of Humoral Antibodies. J Exp Med. 1969; 129(6): 1307-1326. Go to original source... Go to PubMed...
    12. Goldschneider I, Gotschlich E, Artenstein M. Human immunity to the menigococcus. II. Development of natural immunity. J Exp Med. 1969; 129(6): 1327-1348. Go to original source... Go to PubMed...
    13. Uria M, Zhang Q, Li Y, et al. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med. 2008; 205: 1423-1434. Go to original source... Go to PubMed...
    14. Stephens D. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine. 2009; 27(Suppl 2): B71-B77. Go to original source... Go to PubMed...
    15. Strelow V, Vidal J. Invasive meningococcal disease. Arq Neuropsiquiatr 2013; 71(9-B): 653-658. Go to original source... Go to PubMed...
    16. Rožnovský L, Gutvirth J, Beneš J, et al. Standard efektivní klinické péče v přednemocniční neodkladné péči (PNP): Invazivní meningokoková onemocnění. Podpořeno projektem GA ČR reg. č. 310/96/K102. Urgentní medicína. 2002; 3: 18-19. (http://infekce.cz/Standardy/MenPNPDP.pdf).
    17. Novák I. Sepse. In: Intenzivní péče v pediatrii. 2008: 397-405.
    18. Rožnovský L. Meningokokové infekce. In: Beneš J, et al. Infekční lékařství. 2009: 219-223.
    19. Vyhláška č. 473/2008 Sb. o systému epidemiologické bdělosti pro vybrané infekce. Částka 151, příloha č. 6, Systém epidemiologické bdělosti invazivních meningokokových onemocnění (IMO): 8022-8024.
    20. Doporučení České vakcinologické společnosti pro očkování proti invazivním meningokokovým onemocněním. 25. února 2014.(http://www.vakcinace.eu/data/files/downloads/dp_meningovakcinaci_2014final.pdf).

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.